$ cat ./records/gates-foundation-awards-curevac-grants-to-develop-mrna-influenza--2018.txt
Gates Foundation Awards CureVac Grants to Develop mRNA Influenza and Malaria Vaccines
[RECORD.TXT] · cat --full
Building on its 2015 equity investment, the Gates Foundation awarded CureVac two additional grants in February 2018 — one targeting a universal influenza vaccine protective across all influenza A strains, and one targeting Plasmodium falciparum, the deadliest malaria parasite. All resulting products were required to be offered at affordable prices in low- and middle-income countries. The grants reflected the foundation's conviction that mRNA was the most versatile platform for rapid vaccine development against diseases of poverty.
Source: https://www.biospace.com/curevac-to-pursue-innovative-mrna-vaccines-against-flu-and-malaria
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
CEPI Funded Nipah Virus Vaccine Candidate Enters First Human Phase 1 Trial
Next →
Gates Foundation Awards Oxitec $4.1 Million to Engineer Self-Limiting Malaria Mosquito for the Americas
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.